Abstract:Background: Cancers, a group of multifactorial complex diseases, are generally caused by mutation of multiple genes or dysregulation of pathways. Identifying biomarkers that can characterize cancers would help to understand and diagnose cancers. Traditional computational methods that detect genes differentially expressed between cancer and normal samples fail to work due to small sample size and independent assumption among genes. On the other hand, genes work in concert to perform their functions. Therefore, it is expected that dysregulated pathways will serve as better biomarkers compared with single genes.Results: In this paper, we propose a novel approach to identify dysregulated pathways in cancer based on a pathway interaction network. Our contribution is three-fold. Firstly, we present a new method to construct pathway interaction network based on gene expression, protein-protein interactions and cellular pathways. Secondly, the identification of dysregulated pathways in cancer is treated as a feature selection problem, which is biologically reasonable and easy to interpret. Thirdly, the dysregulated pathways are identified as subnetworks from the pathway interaction networks, where the subnetworks characterize very well the functional dependency or crosstalk between pathways. The benchmarking results on several distinct cancer datasets demonstrate that our method can obtain more reliable and accurate results compared with existing state of the art methods. Further functional analysis and independent literature evidence also confirm that our identified potential pathogenic pathways are biologically reasonable, indicating the effectiveness of our method.Conclusions: Dysregulated pathways can serve as better biomarkers compared with single genes. In this work, by utilizing pathway interaction networks and gene expression data, we propose a novel approach that effectively identifies dysregulated pathways, which can not only be used as biomarkers to diagnose cancers but also serve as potential drug targets in the future.

Identifying Cancer Specific Signaling Pathways Based on the Dysregulation Between Genes

Identifying Dysregulated Pathways in Cancers from Pathway Interaction Networks

A novel dysregulated pathway-identification analysis based on global influence of within-pathway effects and crosstalk between pathways.

Subpathway Analysis Based On Signaling-Pathway Impact Analysis Of Signaling Pathway

Pathway-Based Personalized Analysis of Pan-Cancer Transcriptomic Data

Analysis of Whole Genomic Expression Profiles and Screening of the Key Signaling Pathways Associated with Pancreatic Cancer.

A Network-Based Strategy from the Global Perspective for Identification of Risk Pathways in Complex Diseases

Individualized pathway activity algorithm identifies oncogenic pathways in pan-cancer analysis

Identification of Cancer Dysfunctional Subpathways by Integrating DNA Methylation, Copy Number Variation, and Gene-Expression Data

Identification of Cancer Trait Genes and Association Analysis under Pan-Cancer

A Network-Based Pathway-Expanding Approach for Pathway Analysis

Pathway-based analysis of breast cancer.

Oncogenic signaling pathway dysregulation landscape reveals the role of pathways at multiple omics levels in pan-cancer

Identification of Cancer Development Related Pathways Based on Co-Expression Analyses

Identifying novel prostate cancer associated pathways based on integrative microarray data analysis

Analysis of Commonly and Specifically Dysregulated Pathways in Three Women Cancers

PathDriver: Cancer Driver Genes Identification Based on the Metabolic Pathway

Analysis of Tumor Suppressor Genes Based on Gene Ontology and the KEGG Pathway

Discovery of Pan-Cancer Related Genes Via Integrative Network Analysis.

Identifying individualized risk subpathways reveals pan-cancer molecular classification based on multi-omics data

Molecular Signature of Cancer at Gene Level or Pathway Level? Case Studies of Colorectal Cancer and Prostate Cancer Microarray Data.